ipatasertib + cobimetinib + trastuzumab emtansine + atezolizumab + giredestrant + abemaciclib + inavolisib + palbociclib + olaparib + bevacizumab

This is a combination regimen comprising ten anti-cancer drugs: **ipatasertib** (selective AKT inhibitor), **cobimetinib** (MEK1/2 inhibitor), **trastuzumab emtansine** (HER2-targeted antibody-drug conjugate), **atezolizumab** (PD-L1 immune checkpoint inhibitor), **giredestrant** (selective estrogen receptor degrader), **abemaciclib** and **palbociclib** (CDK4/6 inhibitors), **inavolisib** (PI3Kα inhibitor), **olaparib** (PARP inhibitor), and **bevacizumab** (VEGF-A inhibitor). These agents act across multiple oncogenic pathways: PI3K/AKT/mTOR, MAPK/ERK, cell cycle regulation, DNA repair, HER2, immune checkpoint, angiogenesis, and hormone-dependent signaling. The combination does not correspond to a marketed product but consists of individual drugs, each with established roles in targeted therapy, hormonal therapy, immunotherapy, and antiangiogenic therapy, primarily for advanced or metastatic solid tumors.